Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study.
Although low-dose aspirin is widely used, since it is a cheap and effective means of prevention of cardiovascular events, it can cause hemorrhagic gastrointestinal complications. The aim of this study was to evaluate the efficacy of rebamipide in preventing low-dose aspirin-induced gastric injury. A randomized, double-blind, placebo-controlled, crossover trial was performed in twenty healthy volunteers. Aspirin 81 mg was administered with placebo or rebamipide 300 mg three times daily for 7 consecutive days. The rebamipide group exhibited significant prevention of erythema in the antrum compared with the placebo group (p = 0.0393, respectively). Results for the body and fornix did not differ significantly between the placebo and rebamipide groups. In conclusion, short-term administration of low-dose aspirin induced slight gastric mucosal injury in the antrum, but not in the body or fornix. Rebamipide may be useful for preventing low-dose aspirin-induced gastric mucosal injury, especially which confined to the antrum.
Division of Endoscopy, Hokkaido University Hospital, Sapporo 060-8468, Japan.
Shouko
S
Ono
Mototsugu
M
Kato
Aki
A
Imai
Takeshi
T
Yoshida
Jyojyo
J
Hirota
Tamotsu
T
Hata
Kikuko
K
Takagi
Go
G
Kamada
Yuji
Y
Ono
Manabu
M
Nakagawa
Souichi
S
Nakagawa
Yuichi
Y
Shimizu
Hiroshi
H
Takeda
Masahiro
M
Asaka